| 154.74 4.46 (2.97%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 187.87 | 1-year : | 201.76 |
| Resists | First : | 160.85 | Second : | 172.74 |
| Pivot price | 150.26 |
|||
| Supports | First : | 141.61 | Second : | 117.82 |
| MAs | MA(5) : | 148.56 |
MA(20) : | 151.59  |
| MA(100) : | 157.81 |
MA(250) : | 156.42 |
|
| MACD | MACD : | -3.6 |
Signal : | -4.3 |
| %K %D | K(14,3) : | 49.6 |
D(3) : | 35.3 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 200 | Low : | 102 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BLTE ] has closed below upper band by 23.8%. Bollinger Bands are 28% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 156.34 - 156.88 | 156.88 - 157.38 |
| Low: | 145.39 - 146.06 | 146.06 - 146.68 |
| Close: | 153.63 - 154.61 | 154.61 - 155.5 |
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Fri, 30 Oct 2026
Form 4 Belite Bio Inc ADR: Yu-Hsin Lin (Director, CEO) For: 29 October By Investing.com - Investing.com South Africa
Fri, 30 Oct 2026
Form 4 Belite Bio Inc ADR: Wan-Shan Chen (Director) For: 24 September - Investing.com Nigeria
Fri, 30 Oct 2026
Form 4 Belite Bio Inc ADR: Hao-Yuan Chuang (Director, CFO) For: 29 October - Investing.com UK
Thu, 29 Oct 2026
Mizuho Securities Maintains Belite Bio(BLTE.US) With Buy Rating, Cuts Target Price to $221 - Moomoo
Wed, 09 Sep 2026
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross - Yahoo Finance
Wed, 09 Sep 2026
Belite Bio On Track For A Potential Blockbuster Launch In 2027 - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 40 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 43.6 (%) |
| Held by Institutions | 24.2 (%) |
| Shares Short | 1,060 (K) |
| Shares Short P.Month | 1,050 (K) |
| EPS | -2.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15.7 % |
| Return on Equity (ttm) | -22.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.95 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -56.48 |
| PEG Ratio | 0 |
| Price to Book value | 8.02 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|